Pasireotide
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Tumor
Conditions
Carcinoid Tumor, Acromegaly
Trial Timeline
Jun 1, 2006 → Nov 1, 2013
NCT ID
NCT00446082About Pasireotide
Pasireotide is a phase 1 stage product being developed by Novartis for Carcinoid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00446082. Target conditions include Carcinoid Tumor, Acromegaly.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03103009 | Phase 1 | Completed |
| NCT02780882 | Phase 2 | Withdrawn |
| NCT01617733 | Phase 2 | Terminated |
| NCT00698464 | Phase 1 | Completed |
| NCT00434148 | Phase 3 | Completed |
| NCT00446082 | Phase 1 | Completed |
| NCT00171730 | Phase 2 | Completed |
| NCT00171951 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoid Tumor